D₁ Receptor Agonist

SKF-75670 hydrochloride is a Dopamine D1 receptor partial agonist. SKF-75670 hydrochloride is also a Cocaine antagonist.

(Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with K_is of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

A68930, as a dopamine D1 receptor agonist, can be used for the research of bronchiectasis.

Dihydrexidine (DAR-0100) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist with an IC₅₀ of 10 nM for D1 receptor. Dihydrexidine exhibits potent antiparkinsonian activity. Dihydrexidine can stimulate YAP phosphorylation.

Agroclavine acts as an agonist of the D1-dopamine receptor and α₁-adrenergic receptor. Agroclavine enhances the sensitivity of the brain to magnetic fields; it impairs spatial memory without affecting hippocampal long-term potentiation (LTP). Agroclavine exerts bidirectional regulatory effects on immune activity: it enhances NK cell activity with low toxicity under normal conditions, while it inhibits NK cell activity and exhibits significant cardiac and hepatic toxicity under stress conditions. Agroclavine can be used for research on neuroelectrophysiology, learning and memory, and immunoregulation.

Dopamine D3 receptor agonist-2 is a selective dopamine D3 receptor partial agonist with a K_i of 0.268 nM. Dopamine D3 receptor agonist-2 exhibits 29-fold selectivity over dopamine D2 receptor (K_i= 7.67nM).

Adrogolide is an A-86929 (HY-171472) prodrug and dopamine D₁ receptor agonist. Adrogolide is converted rapidly in plasma to A-86929. Adrogolide improves behavioral disability and locomotor activity scores. Adrogolide can also attenuate the ability of Cocaine to induce Cocaine-seeking behavior. Adrogolide can be used in the research of Parkinson's disease.

SKF 38393 ((±)-SKF-38393) hydrobromide is a selective agonist of the dopamine D1 receptor (D1DR) with an IC₅₀ of 110 nM.

A-77636 is an orally active, potent, selective and long-acting dopamine D1 receptor agonist (pEC50 = 8.13; EC50 = 1.1 nM). A-77636 shows the highest affinity (pKi = 7.40 ± 0.09; Ki = 39.8 nM) for the dopamine D1 receptor. A-77636 shows antiparkinsonian activity.

PF-4211 is a selective non-catechol D1R agonist with a K_i value of 2.2 μM.. PF-4211 activates adenylate cyclase by binding to D1R, thereby increasing intracellular cAMP levels. PF-4211 can be used in research related to Parkinson's disease and schizophrenia.

(Rac)-Rotigotine-d₇ (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

SKF83822 hydrobromide is a potent dopamine D1 receptor agonist. SKF83822 hydrobromide activates G_s/_olf/adenylyl cyclase (AC)-coupled D1 receptors, but not phospholipase C (PLC)-coupled D1-like receptors.

(+)-Razpipadon ((+)-PW0464) is a selective D1 dopamine receptor agonist belonging to non-catechol compounds. (+)-Razpipadon activates the G protein pathway, while restricting β-arrestin coupling through the proximity effect of fluoromethyl-TM5, thereby achieving specific regulation of downstream pathways. (+)-Razpipadon can be used in studies related to Parkinson's disease.

Alentemol (U-66444B (free base)) is a blood-brain barrier-permeable dopamine receptor D₁, D₂, D₃, and D₄ agonist. Alentemol inhibits dopamine release, reduces dopamine synthesis, regulates dopamine metabolism, suppresses the impulse activity of dopaminergic neurons, and decreases the impulse frequency of dopaminergic neurons in the substantia nigra pars compacta and ventral tegmental area. Alentemol is applicable to research related to schizophrenia.

Fenoldopam (SKF-82526) is a selective dopamine D₁ receptor agonist. Fenoldopam binds to rat D₁B dopamine receptors (K_d = 11 nM) and human D₁A receptors (K_d = 17 nM) in COS-7 cell membranes expressing the cloned receptors. Fenoldopam modulates dopamine receptor expression, induces vasorelaxation in vascular tissues, reverses glomerular hyperfiltration in rat models, increases intracellular cAMP levels, promotes DARPP-32 phosphorylation in small cell lung cancer (SCLC) cells, inhibits cytokine secretion, and downregulates T cell activation markers in activated human T cells. Fenoldopam can be used for research on hypertension, acute kidney injury, psoriasis, and small cell lung cancer.

FAUC-312, a tetrahydropyrimidine, is a strong and highly selective dopamine D4 receptor partial agonist (K_i=1.5 nM).

Dopamine D3 receptor ligand-5 (13a), a Cariprazine (HY-14763) analogue, is a dopamine D3 receptor ligand, with K_i values of 2.85 nM and 0.14 nM for D₂R and D₃R, respectively.

Alentemol hydrobromide (U-66444B) is a blood-brain barrier-permeable dopamine receptor D₁, D₂, D₃, and D₄ agonist. Alentemol hydrobromide inhibits dopamine release, reduces dopamine synthesis, regulates dopamine metabolism, suppresses the impulse activity of dopaminergic neurons, and decreases the impulse frequency of dopaminergic neurons in the substantia nigra pars compacta and ventral tegmental area. Alentemol hydrobromide is applicable to research related to schizophrenia.